OSIMERT is used for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive (NSCLC) which have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy, as determined by an approved test.
上傳的內容將被移動到此新創建的相冊。 如果你想稍後編輯此相冊,則必須為 建立新帳號 或 登入。
__privacy_notes__